Lopinavir/Ritonavir: Role in the Treatment of HIV-Infected Children

• Sepkowitz KA : One disease, two epidemics – AIDS at 25.N. Engl. J. Med.354, 2411–2414(2006).
   PubMed Web of Science ®Google Scholar
• Merson MH : The HIV-AIDS pandemic at 25 - the global response.N. Engl. J. Med.354, 2414–2417(2006).
   PubMed Web of Science ®Google Scholar
• Palella FJ Jr, Delaney KM, Moorman AC et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med.338, 853–860(1998).
   PubMed Web of Science ®Google Scholar
• Deeks SG : Treatment of antiretroviral-drug-resistant HIV-1 infection.Lancet362, 2002–2011(2003).
   PubMed Web of Science ®Google Scholar
• Calmy A , PascualF, FordN: HIV drug resistance.N. Engl. J. Med.350, 2720–2721(2004).
   PubMed Web of Science ®Google Scholar
• Hartman K , VerweelG, de Groot R, Hartwig NG: Detection of lipoatrophy in human immunodeficiency virus-1-infected children treated with highly active antiretroviral therapy. Pediatr. Infect. Dis. J.25, 427–431(2006).
   PubMed Web of Science ®Google Scholar
• van Rossum AM , FraaijPL, de Groot R: Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect. Dis.2, 93–102(2002).
   PubMed Web of Science ®Google Scholar
• Cvetkovic RS , GoaKL: Lopinavir/ritonavir: a review of its use in the management of HIV infection.Drugs63, 769–802(2003).
   PubMed Web of Science ®Google Scholar
• Zeldin RK , PetruschkeRA: Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients.J. Antimicrob. Chemother.53, 4–9(2004).
   PubMed Web of Science ®Google Scholar
• Mo H , KingMS, KingK, MollaA, BrunS, KempfDJ: Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.J. Virol.79, 3329–3338(2005).
   PubMed Web of Science ®Google Scholar
• Crommentuyn KM , KappelhoffBS, Mulder JW et al.: Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients. Br. J. Clin. Pharmacol.60, 378–389(2005).
   PubMed Web of Science ®Google Scholar
• Capparelli EV , HollandD, OkamotoCet al.: Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS19, 949–952(2005).
   PubMed Web of Science ®Google Scholar
• Jullien V , UrienS, HirtDet al.: Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years. Antimicrob. Agents Chemother.50, 3548–3555(2006).
   PubMed Web of Science ®Google Scholar
• Bergshoeff AS , FraaijPL, NdagijimanaJet al.: Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug–drug interaction in HIV-1-infected children. J. Acquir. Immune Defic. Syndr.39, 63–68(2005).
   PubMed Web of Science ®Google Scholar
• Ramos JT , de Jose MI, Polo R et al.: RecommendationsoftheCEVIHP/SEIP/AEP/PNSonantiretroviraltreatmentinHIV-infectedchildrenandteenagers]. Enferm. Infecc. Microbiol. Clin.23, 279–312(2005).
   PubMedGoogle Scholar
• Rosso R , Di Biagio A, Dentone C et al.: Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration. J. Antimicrob. Chemother.57, 1168–1171(2006).
   PubMed Web of Science ®Google Scholar
• Saez-Llorens X , ViolariA, DeetzCOet al.: Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J.22, 216–224(2003).
   PubMed Web of Science ®Google Scholar
• Resino S , BellónJM, RamosJTet al.: Positive virologic outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children. A prospective cohort study. J. Antimicrob. Chemother.54, 921–931(2004).
   PubMed Web of Science ®Google Scholar
• Resino S , BellonJM, Munoz-Fernandez MA: Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency. J. Antimicrob. Chemother.57, 579–582(2006).
   PubMed Web of Science ®Google Scholar
• Ramos JT , De Jose MI, Duenas J et al.: Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals. Pediatr. Infect. Dis. J.24, 867–873(2005).
   PubMed Web of Science ®Google Scholar
• Delaugerre C , TeglasJP, TreluyerJMet al.: Predictive factors of virologic success in HIV-1-Infected children treated with lopinavir/ritonavir. J. Acquir. Immune Defic. Syndr.37, 1269–1275(2004).
   PubMed Web of Science ®Google Scholar
• Galan I , JimenezJ, González-RiveraMet al.: Virological phenotype switches under salvage therapy with lopinavir–ritonavir in heavily pretreated HIV-1 vertically infected children. AIDS18, 247–255(2004).
   PubMed Web of Science ®Google Scholar
• Resino S , GalanI, PerezAet al.: Immunological changes after highly active antiretroviral therapy with lopinavir–ritonavir in heavily pretreated HIV-infected children. AIDS Res. Hum. Retroviruses21, 398–406(2005).
   PubMed Web of Science ®Google Scholar
• Landay A , da Silva BA, King MS et al.: Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir–ritonavir treatment. Clin. Infect. Dis.44, 749–754(2007).
   PubMed Web of Science ®Google Scholar
• Arribas JR , PulidoF, DelgadoRet al.: Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J. Acquir. Immune Defic. Syndr.40, 280–287(2005).
   PubMed Web of Science ®Google Scholar
• Walmsley S , BernsteinB, KingMet al.: Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N. Engl. J. Med.346, 2039–2046(2002).
   PubMed Web of Science ®Google Scholar
• Resino S , BellonJM, RamosJTet al.: Salvage lopinavir-ritonavir therapy in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J.23, 923–930(2004).
   PubMed Web of Science ®Google Scholar
• Eron J Jr, Yeni P, Gathe J Jr et al.: The KLEAN study of fosamprenavir–ritonavir versus lopinavir-ritonavir, each in combination with abacavir–lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet368, 476–482(2006).
   PubMed Web of Science ®Google Scholar
• Temesgen Z , CainelliF, PoeschlaEM, VlahakisSA, VentoS: Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults.Lancet Infect. Dis.6, 496–507(2006).
   PubMed Web of Science ®Google Scholar
• Panagopoulos P , TsiodrasS, AntoniadouAet al.: Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavir–ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors. Clin. Microbiol. Infect.12, 486–489(2006).
   PubMed Web of Science ®Google Scholar
• Montes ML , PulidoF, BarrosCet al.: Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors. J. Antimicrob. Chemother.55, 800–804(2005).
   PubMed Web of Science ®Google Scholar
• Carter RJ , WienerJ, AbramsEJet al.: Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999–2004: a longitudinal analysis. J. Acquir. Immune Defic. Syndr.41, 453–460(2006).
   PubMed Web of Science ®Google Scholar
• Vaclavikova J , MachalaL, StankovaMet al.: Response of HIV positive patients to the long-term salvage therapy by lopinavir/ritonavir. J. Clin. Virol.33, 319–323(2005).
   PubMed Web of Science ®Google Scholar
• Monno L , SaracinoA, ScudellerLet al.: HIV-1 Phenotypic susceptibility to lopinavir (lpv) and genotypic analysis in LPV/r-naive subjects with prior protease inhibitor experience. J. Acquir. Immune Defic. Syndr.33, 439–447(2003).
   PubMed Web of Science ®Google Scholar
• de Mendoza C , ValerL, BachelerL, Pattery T, Corral A, Soriano V: Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance. AIDS20, 1071–1074(2006).
   PubMed Web of Science ®Google Scholar
• Kempf DJ , IsaacsonJD, KingMSet al.: Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antivir. Ther.7, 165–174(2002).
   PubMed Web of Science ®Google Scholar
• Jimenez JL , ResinoS, Martinez-ColomA, BellonJM, Munoz-FernandezMA: Mutations at codons 54 and 82 of HIV protease predict virological response of HIV-infected children on salvage lopinavir/ritonavir therapy.J. Antimicrob. Chemother.56(6), 1081–1086(2005).
   PubMed Web of Science ®Google Scholar
• Parkin NT , ChappeyC, PetropoulosCJ: Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance.AIDS17, 955–961(2003).
   PubMed Web of Science ®Google Scholar
• de Mendoza C , Martin-CarboneroL, BarreiroPet al.: Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families. HIV Clin. Trials3, 304–309(2002).
   PubMedGoogle Scholar
• Bongiovanni M , BiniT, AdorniFet al.: Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations. Antivir. Ther.8, 209–214(2003).
   PubMed Web of Science ®Google Scholar
• Liu TF , ShaferRW: Web resources for HIV type 1 genotypic-resistance test interpretation.Clin. Infect. Dis.42, 1608–1618(2006).
   PubMed Web of Science ®Google Scholar

Website

• Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection http://AIDSinfo.nih.gov
   Google Scholar